Innoviva, Inc. (INVA)

↓ Download CSV

CIK 0001080014 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Innoviva, Inc. reported revenue of $411.33M, up 14.7% from the prior year. The company was profitable, with a net margin of 65.9% and a gross margin of 74.8%.

Key ratios (FY2025)

74.8%
Gross margin
39.8%
Operating margin
65.9%
Net margin
23.1%
Return on equity
+14.7%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$411.33M$358.71M$310.46M$331.34M$391.87M$336.79M$261.02M$261.00M$217.22M$133.57M
Gross Profit$307.67M$296.21M$246.04M
Operating Income$163.75M$166.87M$113.89M$375.10M$321.12M$246.36M$238.25M$183.60M$108.99M
Net Income$271.17M$23.39M$179.72M$220.26M$368.84M$293.81M$190.99M$406.33M$134.27M$59.54M
EPS (Diluted)$3.30$0.36$2.20$2.37$2.87$2.02$1.43$3.53$1.17$0.53
Total Assets$1.64B$1.30B$1.24B$1.23B$926.39M$999.57M$724.83M$548.19M$367.34M$379.00M
Shareholders' Equity$1.17B$691.16M$565.79M$414.74M$539.91M$313.50M$153.58M-$242.86M-$352.99M
Cash & Equivalents$550.94M$304.96M$193.51M$291.05M$201.53M$246.49M$278.10M$62.42M$73.34M$118.02M
Operating Cash Flow$196.93M$188.69M$141.06M$201.73M$363.81M$313.11M$257.46M$223.53M$141.75M$60.98M
Capital Expenditures$1.13M$270.0K$411.0K$67.0K$0$13.0K$12.0K$0$0$278.0K
Shares Outstanding84.76M74.19M86.88M95.25M94.31M113.55M113.41M113.41M119.87M123.23M
Dividends Per Share$0.00$0.00